Addiction

Buprenorphine is available either in a weekly injection formulation and a monthly formulation for patients already being treated with buprenorphine.

The petition with the US DEA is aiming to remove dual orexin receptor antagonist medications from the Controlled Substances Act due to negligible potential for abuse.

The proportion of AUD treatment engagement did not differ between the 2 time periods, but intervention increased intermediate outcomes, including screening, new AUD diagnosis, and treatment initiation.

Future research could explore the factors contributing to this disparity and identify effective interventions to reduce tobacco use in this population.

Personalized text message-based smoking cessation intervention was found to be more effective than the non-personalized text message approach, especially among smokers with low nicotine dependence and strong quitting intention.

A study examining the COVID-19 pandemic finds that substance use declined substantially across nearly all categories in 2018-2019 vs 2020 among youth and young adults.

It wasn't the unavailability of varenicline, but the inaccessibility, that perpetuated the reduced prevalence of prescriptions. Investigators speculated that patient, clinician awareness and concerns related to nitrosamine were contributing factors.

E-cigarettes are marketed as an alternative to tobacco, though discussion within the research community emphasizes the inconsistencies in evidence regarding health and addiction among users.

Pregnant individuals with opioid use disorder are commonly treated with methadone.

The receipt of DAA treatment within 1 year was 7% for patients entering the cohort in 2014, compared to 33% in 2015, 53% in 2016, and 56% in 2017.

A retrospective analysis of controlled drug dispensation shows conflicting rates of prescriptions to teenagers and young adults.

CDC investigators stated that the expansion of telehealth strategies is “urgently needed” to provide medications for opioid use disorder because it could increase retention in care and improve outcomes for OUD.

The mean daily alcohol consumption was also lower in the psilocybin group compared to the placebo group.

Reductions in prescribed benzodiazepines were especially noted in continuing prescriptions.

New comparative effectiveness data go against CDC recommendations for tapering or abruptly ending long-term opioid prescription.

After March 2020, overdose deaths not involving methadone continued to increase whereas methadone-involved overdose deaths remained stable.

William F. Peacock, MD; Conar Fitton, MD; and Neel Mehta, MD, consider potential patient preferences when choosing oral vs subcutaneous peripheral μ-opioid receptor antagonists.

A multidisciplinary panel shares individual experience with using oral peripherally acting μ-opioid receptor antagonists in managing opioid-induced constipation.

According to a new report from the CDC, as fatal drug overdoses increase across the board, the Black and Indigenous communities represent a significantly greater death rates.

William F. Peacock, MD; Conar Fitton, MD; and Neel Mehta, MD, review the rationale for the use of μ-opioid receptor agonists for the treatment of opioid-induced constipation.

Experts in gastroenterology review the challenges associated with switching therapies during inpatient and outpatient care for patients with opioid-induced constipation.

Data suggest continued prescribing, not initial prescribing, is linked to opioid addiction risk among exposed family members.

William F. Peacock, MD; Conar Fitton, MD; and Neel Mehta, MD, discuss the multidisciplinary approaches to selecting therapies for patients with opioid-induced constipation.

A multidisciplinary panel shares practical approaches to treating patients with opioid-induced constipation and challenges with patient communication.

Buprenorphine has shown to be effective and has the potential for widespread use to address the opioid epidemic. A subset of individuals with OUD have been acquiring it without a prescription.

An Ohio State researcher discusses a new medical center education program for navigating addiction risk in pain patients.

William F. Peacock, MD; Conar Fitton, MD; and Neel Mehta, MD, reviews the position of pharmacies in providing patients with opioid-induced constipation with the necessary medication to decrease hospitalization and cost of medication.

Experts in gastroenterology discuss the quality of life and perspective of patients with opioid-induced constipation.

Varenicline was efficacious at weeks 12, 24, and 52 of the trial compared with placebo in a smoking cessation program.

During the analysis, investigators became fascinated by how many patients entered the buprenorphine treatment program for OUD having already been taking the drug without a prescription.